Previous Article | Next Article 
J Virol, August 1998, p. 6858-6866, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
CXCR4 Is Required by a Nonprimate Lentivirus: Heterologous
Expression of Feline Immunodeficiency Virus in Human, Rodent, and
Feline Cells
Eric M.
Poeschla1,* and
David J.
Looney1,2,*
Department of Medicine, University of
California, San Diego,1 and
Infectious
Diseases Division, Veterans Administration Medical
Center,2 La Jolla, California
Received 30 September 1997/Accepted 12 May 1998
 |
ABSTRACT |
A heterologous feline immunodeficiency virus (FIV) expression
system permitted high-level expression of FIV proteins and efficient production of infectious FIV in human cells. These results identify the
FIV U3 element as the sole restriction to the productive phase of replication in nonfeline cells. Heterologous FIV
expression in a variety of human cell lines resulted in
profuse syncytial lysis that was FIV env specific, CD4
independent, and restricted to cells that express CXCR4, the
coreceptor for T-cell-line-adapted strains of human
immunodeficiency virus. Stable expression of human CXCR4 in
CXCR4-negative human and rodent cell lines resulted in extensive
FIV Env-mediated, CXCR4-dependent cell fusion and infection. In feline
cells, stable overexpression of human CXCR4 resulted in increased
FIV infectivity and marked syncytium formation during FIV
replication or after infection with FIV Env-expressing vectors. The
use of CXCR4 is a fundamental feature of lentivirus biology independent of CD4 and a shared cellular link to infection and
cytopathicity for distantly related lentiviruses
that cause AIDS. Their conserved use implicates chemokine receptors as
primordial lentivirus receptors.
 |
INTRODUCTION |
The nonprimate lentiviruses include
the ungulate lentiviruses and feline immunodeficiency virus (FIV). FIV
was discovered in 1986 as a cause of acquired immune deficiency and
neurological disease in domestic cats (Felis catus)
(31). FIV and human immunodeficiency virus type 1 (HIV-1)
are the only lentiviruses that cause selective loss of the
CD4+ T-cell subset and AIDS in naturally infected host
species. However, in contrast to the primate lentiviruses, FIV does not
use CD4 for entry and displays broader cellular tropism in vivo,
infecting large numbers of B cells and CD8+ T cells as well
as CD4+ T cells and macrophages (9, 26).
Uncoupling of selective CD4 depletion from the use of the CD4 molecule
for entry is one of the most interesting features of the FIV model
because it suggests that there exist basic lentivirus pathogenetic
pathways that are CD4 molecule independent yet affect the
CD4+ T-cell subset preferentially. Primary cell surface
receptors have not been established for any of the nonprimate
lentiviruses (13, 44).
Nucleotide sequence comparisons indicate that FIV is more closely
related to the ungulate lentiviruses than to HIV or simian immunodeficiency virus (28). Phylogenetic and
epidemiological data also suggest an ancient evolutionary divergence of
FIV from ancestors of the primate lentiviruses (1, 8, 11, 29, 39). While serological cross-reactivity between structural
proteins of FIV and ungulate lentiviruses has been observed, none is
detectable between FIV and the primate lentiviruses (14, 27,
39). In addition, FIV encodes a dUTPase, a fifth
pol-encoded enzymatic activity that is found only in the
nonprimate lentiviruses (42). Although FIV infects 2 to 20%
of domestic-cat populations as well as many free-roaming nondomestic
members of the family Felidae worldwide, there is no
evidence for FIV infection of nonfelids (29, 30). Neither
human seroconversion nor any other detectable evidence of human
infection or disease occurs, despite frequent exposure of humans to FIV
by biting, the principal route of natural feline transmission (sexual
transmission does not occur to any extent) (30).
At the human cellular level, restrictions to both viral production and
infection by nonprimate lentiviruses are evident, although the
mechanisms are not well understood (12, 22, 40). Reported obstacles to FIV expression in human cells have included poor Rev
function (40) and poor long terminal repeat (LTR)
transcriptional activity (22, 35). Because of these blocks,
expression of the nonprimate lentivirus Rev-dependent structural
proteins in nonhost animal cells has received little investigation. In
the present study, we developed an expression system which revealed that human cells support high-level production of Rev-dependent FIV
structural proteins and of infectious virus when the transcriptional inactivity of the FIV LTR is bypassed through promoter (U3
element) substitution. In addition, these chimeric constructs produced profuse syncytia in human as well as feline cells, a
surprising finding that prompted further investigation of the molecular
basis for this broad cytopathicity.
Expressing FIV directly in cells of a given species avoids the
potential ambiguities of studies employing interspecies coculture, including the identity of the cells undergoing fusion and the potentially confounding role of xenotropic retroviruses. For example, feline cells contain multiple copies of an inducible, xenotropic, replication-competent type C endogenous retrovirus (RD114) that is
related at the nucleotide sequence level to a primate retrovirus (baboon endogenous virus), replicates in human cells, and
phenotypically mixes with FIV and other retroviruses (20,
38).
 |
MATERIALS AND METHODS |
Cells, stable cell lines, and viruses.
Cell lines used were
American Type Culture Collection lines propagated in Dulbecco minimal
Eagle medium supplemented with glutamine, pyruvate, antibiotics, and
10% heat-inactivated fetal calf serum. Plasmid pZ.CXCR4 has the
structure LTR-cxcr4-IRES-neo-LTR (where IRES is a
poliovirus internal ribosome entry site) to permit selection for a
bicistronic message encoding CXCR4 and neomycin phosphotransferase and
was constructed by cloning the human CXCR4 cDNA (obtained from A. Gervaix) in place of the hygromycin resistance gene of retroviral
vector pJZ308 (47). G418-stable lines were generated by
transduction of the indicated cells with supernatant obtained from
PA317 cells cotransfected with pZ.CXCR4 and a vesicular stomatitis
virus glycoprotein G (VSV-G) expression plasmid, pHCMV-G, followed by selection and maintenance in medium containing G418 at 400 to 1,000 µg/ml. All lines were derived from at least 1,000 separate
colonies. Infectious FIV was produced in 293T cells by calcium
phosphate transfection of CT5 (10 µg/75-cm2 flask),
harvesting at 24 to 48 h, centrifugation at 1,000 × g, and filtration through a 0.45-µm-pore-size filter. For production of
FIV in Crandell feline kidney (CrFK) cells, chronic infection of CrFK
cells was established by transfection with p34TF10 and passaging;
supernatant was harvested, cleared, filtered (0.45-µm pore size), and
stored at
80°C.
Chimeric FIV plasmid construction.
The numbering system used
is based on that of Talbott et al. (39). CF1 was generated
by blunt-end ligation of the SacI-EspI fragment
of p34TF10 between the NotI and XbaI sites in the
polylinker of the cytomegalovirus (CMV) expression plasmid pRc/CMV
(Invitrogen). The 5' junction is 97 nucleotides (nt) upstream of the
major splice donor site. CF1 has been deleted of both LTRs except for
the 89-nt portion of the 3' U3 that overlaps rev and lacks
the basis for reverse transcription and integration. CF1
env has an
875-nt deletion in env which spans the SU-TM junction and is
also frameshifting (a SacII linker was inserted between the
two PflMI sites of the subcloned env gene).
CF1
SU and CF1
SU.fs are deleted of nt 1059 to 1596 of SU
(encompassing the V3 and V4 hypervariable loops). To produce the fusion
of the human CMV immediate-early promoter (hCMVIEp) to the FIV genome
over the TATA box illustrated in Fig. 1, PCR was performed with a
SacI-tailed sense PCR primer homologous to the
nucleotides immediately downstream from the FIV TATA box (5'-ATATAGAGCTCTGTGAAACTTCGAGGAGTCTC-3') in combination with
an antisense PCR primer (5'-CCAATCTCGCCCCTGTCCATTCCCC-3')
homologous to the opposite strand of the FIV gag gene
and 3' to the leader sequence XhoI site. The 450-bp PCR
product was first digested with XhoI (without
SacI, to avoid cleaving the overlapping SacI site
3 nt downstream) and then subsequently digested with SacI to
generate the 5' cloning end. The 310-bp cleavage product was cloned
into the SacI-XhoI backbone of pRc/CMV,
generating plasmid CRF1. SalI-tailed PCR primers
5-TATATAGTCGACTAGGGACTGTTTACGAAC-3' and
5'-ATATATAGTCGACGCGGCCGCTGCGAAGTTCTCG-3' were then used to amplify the 3' FIV LTR; after SalI digestion, the PCR
product was ligated into the XhoI site of CRF1. The
resulting plasmid, CRF(L), has the 5'-LTR fusion and a wild-type 3'
LTR. The major coding region of the FIV 34TF10 genome (the 8,845-nt
BbeI-EspI fragment) was then inserted into the
BbeI-EspI backbone of CRF(L), producing CT5,
which encodes full-length, infectious FIV. The 438-ntpol
deletion in CF1
pol and CT5
pol was constructed by deleting the
NheI-Bsu36I fragment (nt 3122 to 3573). CF1
env
was generated by a series of three-part ligations that deleted an
875-nt PflmI fragment of FIV env (nt 7322 to
8197) and inserted a SacII linker to produce a frameshift.
The shorter, 539-nt deletion (nt 7321 to 7860) confined to SU (in
CF1
SU and CF1
SU.fs) was produced by PCR amplification of a
segment including env and the 3' LTR (using
SacI-tailed sense primer
5'-ATATACCGCGGTCTTGTACATCTGACTTGCCATCG-3' and antisense
primer 5'-ATATATAGTCGACCGGCCGTGCGAAGTTCTCGG-3'), digestion
with SacII- and EagI, and insertion of the
resulting fragment downstream of the SacII site in CF1 in
several steps; blunted closure of the SacII site restored an
open reading frame.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 1.
Diagram of chimeric FIV expression plasmids. CT5
contains the illustrated fusion of the hCVMIEp to the FIV genome at
position 14 between the TATA box and the mRNA cap site. See Materials
and Methods for details of construction. RRE, Rev response element.
|
|
Radioimmunoprecipitation and RT assays.
Radiolabeling with
[35S]cysteine and [35S]methionine in
cysteine- and methionine-free medium with 7.5% dialyzed fetal bovine
serum was performed for 5 h after a 1-h preincubation in this
medium without isotope. Cells were washed, detached with 5 mM EDTA in phosphate-buffered saline (PBS), and lysed in 1 ml of
radioimmunoprecipitation buffer containing the protease inhibitors
phenylmethylsulfonyl fluoride and leupeptin. Subsequent steps were
performed at 0 to 4°C in the presence of freshly added protease
inhibitors. Cell lysates were precleared with normal cat serum and
protein A-Sepharose for 2 h and then incubated overnight with
continuous mixing after addition of 10 µl of FIV-infected cat plasma.
Antibody-protein complexes were precipitated with protein A-Sepharose.
After repeated washing, samples were heated to 95°C for 5 min in
sodium dodecyl sulfate (SDS) loading buffer and electrophoresed with
prestained protein size markers (Bio-Rad) in SDS-10 or SDS-12.5%
polyacrylamide gels. Reverse transcriptase (RT) assays were performed
in triplicate with a 32P-based microtiter assay
(46).
Transfection assays and transfection efficiency
controls.
Comparisons of transfected cells were
controlled by cotransfection of a GFP or LacZ reporter plasmid under
the control of hCMVIEp as 10% of the input DNA; only experiments with
transfection efficiencies varying <10% between compared cell lines
are reported. Where syncytial destruction of the monolayer was
extensive at 24 h for CF1, comparative transfection efficiencies
were assayed in wells transfected in parallel and maintained in the
presence of a 1:300 dilution of FIV-infected domestic-cat plasma to
inhibit syncytium formation. Transfections were performed by calcium
phosphate precipitation except for U87MG and U87MG.CXCR4 cells, which
were electroporated (210 V).
FIA and titration of FIV and FIV-enveloped vectors.
For
titration of replication-competent FIV, each line was seeded into
48-well plates at 104 cells per well and infected in
sextuplicate the next day with serial fourfold dilutions. For FIA, the
focal infectivity assay (FIA), foci were scored by immunoperoxidase
staining 42 h later, employing FIV Petaluma cat serum and a
secondary horseradish peroxidase-conjugated goat antibody to feline
immunoglobulin G (ICN Pharmaceuticals) as described by Remington et al.
(34). With this protocol, no background staining was seen in
any cell line. For endpoint dilution, cells were infected in 48-well
plates in the same manner but allowed to proliferate for 4 weeks, with
trypsinization and splitting at 4- to 5-day intervals; positive wells
were scored by RT production, and titers were calculated by the method
of Spearman (36). To generate FIV-enveloped vectors,
CT5
pol and CF1
env were cotransfected into 293T cells. Serial
fivefold dilutions of filtered supernatant collected at 48 h
posttransfection were used to infect 24-well plates seeded 24 h
earlier with 3 × 104 cells of each cell line. Foci
were scored by FIA 48 h after infection.
Production and titration of pseudotyped CT5
pol vector.
To
produce VSV-G-pseudotyped CT5
pol, 293T cells were cotransfected
with CF1
env, CT5
pol, and the VSV-G expression plasmid pHCMV-G
(10). At 48 to 96 h after transfection, supernatants were cleared by centrifugation, filtered (0.45-µm pore size), aliquoted, and stored at
80°C. Serial fourfold dilutions were used
to infect 24-well plates seeded 24 h earlier with 3 × 104 cells of each cell line. Foci were scored by FIA
48 h after infection. Control experiments showed that no
background staining occurred in uninfected cells, in cells infected
with heat-treated (56°C, 30 min) vector, or in cells exposed to
supernatant generated with only CT5
pol and pHCMV-G (leaving the
gag-pol expression plasmid out).
Human-feline cell coculture.
Cell lines were each plated
(3 × 105 cells) in six-well plates. The next day,
105 3201-FIV cells (ATCC CRL 10909, maintained in 10%
RPMI) were added, in a 1:1 mixture of 10% RPMI and 10% Dulbecco
minimal Eagle medium, per well.
Analysis of CXCR4 mRNA expression.
RNA was prepared by
direct addition of TRIZOL reagent (Gibco BRL) to 106 cells
in accordance with the manufacturer's instructions. RNA was dissolved
in 50 µl of RNA transcription buffer, treated with 20 U of RNase-free
DNase (Boehringer Mannheim) for 30 min at 37°C, and then heated to
70°C for 10 min. For reverse transcription-PCR, 10 µl of each
DNase-treated RNA sample was reverse transcribed at 48°C for 45 min
in a 50-µl reaction volume containing 1× Promega Access
AMV/Tfl buffer, 1 mM MgSO4, 200 µM each
deoxynucleoside triphosphate 50 pmol of each primer, 5 U of avian
myeloblastosis virus RT, and 5 U of Tfl polymerase and then
subjected to 40 cycles of 94°C for 30 s, 55°C for 45 s,
and 68°C for 1 min followed by a final 7-min extension at 72°C.
Primers used for amplification of human CXCR4 were
5'-GAAGCTGTTGGCTGAAAAGG-3' and
5'-GATCCCAATGTAGTAAGGCAGC-3'. Primers used for amplification
of human CXCR4 were 5'-GATAACTACACCGAAGATGACTTG-3' and
5'-AAGATGAAATCAGGAATAGTCAAC-3'. Primers used for
amplification of ribosomal protein L32 were
5'-ATGCCCAACATTGGTTATGG-3' and
5'-ATTTGTTGCACATCAGCAGC-3'. To confirm the adequacy of the
DNase treatment, samples were also subjected to PCR without addition of
avian myeloblastosis virus RT. For analysis, 10 µl of each product
was run on a 6% polyacrylamide gel and stained with SYBR Green dye
(Molecular Probes, Eugene, Oreg.). Gels were imaged with a Speedlite
Platinum system (LightTools Research, San Diego, Calif.), and bands
were quantitated with ImageQuant software (Molecular Dynamics).
Expression of CXCR4 RNA was plotted relative to L32 mRNA expression,
subtracting the local background from each window and correcting for
relative band sizes (332 bp for human CXCR4, 497 bp for feline CXCR4,
and 120 bp for L32).
Flow cytometric analysis of cell surface CXCR4 expression.
Cells (106) were detached with 4 mM EDTA in PBS, incubated
with 20 mg of anti-CXCR4 monoclonal antibody (no. 36195X,
R-phycoerythrin-conjugated 12G5 clone mouse immunoglobulin
G2A(
); Pharmingen, San Diego, Calif.) in a final volume of 300 ml of
PBS with 1% fetal bovine serum for 1 h at 4°C, washed, and
fixed with 1% paraformaldehyde. Flow cytometric analysis was performed
on a Coulter Elite fluorescence-activated cell sorter apparatus, using
a 488-nm argon laser for excitation; 5,000 cells were counted for each
sample. Relative CXCR4 expression was determined by calculating the
increase in the mean fluorescence intensity relative to that of the
control unstained cells for each cell type.
 |
RESULTS |
Heterologous expression of the FIV genome.
FIV 34TF10, a cell
culture-adapted FIV clone with a broadly tropic envelope glycoprotein
(39, 43), was modified for the present work. Although FIV
34TF10 productively infects CrFK cells, neither 34TF10 nor other
domestic-cat strains or clones are grossly cytolytic in this cell line.
Scattered, small, multinucleate giant cells can be detected, but
extensive cell death and disruption of the CrFK monolayer do not occur
and chronic infection is readily established (2-4, 39, 41).
To determine if substitution of an alternative promoter for the FIV LTR
was feasible and would enable initiation of the productive phase of FIV
replication in both human and feline cells, the 34TF10 molecular clone
was modified as diagrammed in Fig. 1. The
hCMVIEp was arranged to replace either the entire FIV LTR (in CF1) or only the 5' U3 element by the precise fusion of the TATA box to the R
repeat (plasmids CT5 and CT5
pol). The fusion in CT5 aligns the FIV
mRNA cap site downstream of the hCMVIEp TATA box such that the
nucleotide spacing between the replaced FIV TATA box and the
transcription start site is preserved.
In both human and feline cells, transfection of CF1 or CT5 resulted in
substantial FIV protein expression with a wild-type
pattern as assessed
by radioimmunoprecipitation (Fig.
2),
high
levels of
pol-specific Mg
2+-dependent RT
activity (Fig.
3), and profuse syncytia.
Expression
by CF1 and CT5 exceeded LTR-directed expression by
p34TF10 in
cells of both feline and human origin. p34TF10 expression
was
undetectable in 293 cells even after prolonged film exposure
(Fig.
2A). Expression of FIV proteins by p34TF10 in HeLa cells was
detectable
by radioimmunoprecipitation, but at levels lower than those
of
the hCMVIEp chimeras (Fig.
2B and
3).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 2.
Expression and processing of FIV proteins in transfected
human and feline cells, assessed by radioimmunoprecipitation with FIV
(Petaluma strain)-infected domestic-cat plasma. 293 cells (panel A, all
8 lanes), HeLa (panel B, lanes 1 to 3), and CrFK cells (panel B, lanes
4 to 6) were transfected with 5 µg of the indicated plasmids by
calcium phosphate precipitation in 25-cm2 flasks. At
27 h (293 cells) or 44 h (HeLa and CrFK cells) after
transfection, cells were radiolabeled and immunoprecipitated (see
Materials and Methods). The HeLa cell lysate used for lane 1 in panel B
was derived from approximately 15 to 25% of the amount of cells in the
other lanes because of the loss of cells to extensive syncytial lysis.
The data from one of two radioimmunoprecipitations performed are shown;
each yielded the same results. Shown on the left are the positions of
molecular mass markers (in kilodaltons).
|
|

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Supernatant Mg2+-dependent RT activity
measured 36 h after transfection of the indicated plasmids in
CrFK, HeLa, and 293 cells. Widespread syncytia were present in
cells transfected with CT5, CF1, CF1 pol, or pHCMV-G. The
last two plasmids were included as controls for cell lysis to verify
the viral specificity of the RT activity. Supernatants from chronically
infected CrFK cells and H9 cells (infected 2 weeks earlier with HIV-1
at an MOI of 1) were also assayed for comparison (right side of
figure). Each value is the mean of triplicate measurements ± the
standard error of the mean.
|
|
Transfection of CT5 into human cells resulted in the production of
infectious FIV. Transfection of either 34TF10 or CT5 into
CrFK cells,
or cell-free passage of virus from CT5-transfected
human cells to CrFK
cells, led to the establishment of a persistent
infection with high
levels of RT production (>5 × 10
5 cpm/ml) by days 7 to 14. However, consistent with previous studies
(
2-4,
39,
41), a minimal cytopathic effect was seen during
either acute or
chronic infection of CrFK cells (mean ± standard
deviation, 6 to
12 ± 4 syncytia, with four to eight nuclei each,
per
9.6-cm
2 well of a six-well plate). Transfection of CT5 in
human 293 cells
yielded supernatant containing nearly 10
6
cpm of RT activity per ml (Fig.
3) and infectious FIV with titers
of >10
5 focus forming units (FFU)/ml on CrFK cells, as
determined by
a previously described FIV-specific FIA (
34).
CF1, which is designed to supply FIV proteins in
trans,
lacks the basis for reverse transcription and integration because
of
the deletion of both LTRs. CF1 produced high levels of RT activity
(Fig.
3) but did not produce infectious virus. Passage of
>10
7 cpm of RT activity from CF1-transfected 293T cells to
5 × 10
6 CrFK cells or to human cells (HeLa, 293, H9,
Molt4, SupT1, or
U937) resulted in a lack of syncytia and no RT
production. The
adherent cell lines were also examined and found to be
negative
by the immunoperoxidase FIA, which has a sensitivity of <5
infectious
units per ml on CrFK cells (
34).
Syncytium induction in human and feline cells.
Enabling
efficient FIV expression in human cells revealed surprising
cytopathicity of the FIV envelope glycoprotein. Transfection of CF1,
CF1
pol, or CT5, but not 34TF10, into human cells resulted in
explosive syncytium formation within 12 to 18 h. HeLa and 293 cell
monolayers were reproducibly 90 to 95% destroyed by syncytial lysis
within 36 to 72 h after transfection of CF1 (Fig.
4A and B and data not shown). In CrFK
cells, transfection of the four plasmids consistently produced >2 log
units fewer and smaller (4 to 12 nuclei) syncytia without disruption of
the monolayer.

View larger version (111K):
[in this window]
[in a new window]
|
FIG. 4.
Fusogenic activity of FIV envelope in human, feline, and
rodent cell lines and effect of stable human CXCR4 coexpression. Each
left-right photo pair is presented for comparison. (A to F) Cells
transfected with plasmids (indicated below) and stained with crystal
violet 24 to 48 h later. (A) HeLa cells transfected with
CF1 env; (B) HeLa cells transfected with CF1; (C to F)
CF1-transfected 3T3 cells, 3T3.CXCR4 cells, HOS cells, and HOS.CXCR4
cells, respectively. (G to J) Cells infected at equal MOI with
VSV-G-pseudotyped env expression vector CT5 pol and
stained by the FIV Env-specific immunoperoxidase assay 24 to 48 h
later. (G) U87MG cells; (H) U87MG.CXCR4 cells; (I) CrFK cells; (J)
CrFK.CXCR4 cells. Generation and characterization of CXCR4-expressing
cell lines are described in the legend to Fig. 6. In addition to the
syncytia seen, large areas of panels B, F, H, and J are denuded because
of detachment of syncytia prior to or during staining. Transfections
were controlled for efficiency as described in Materials and Methods.
|
|
To determine if syncytium induction by CF1 and CT5 in human
and feline cells was mediated specifically by the FIV envelope
glycoprotein,
env mutants with deletions either spanning
both
SU and TM domains (CF1

env) or only in the SU domain
(CF1

SU and
CF1

SU.fs) were constructed (Fig.
1). The two
frameshifting
env deletions (CF1

env and CF1

SU.fs)
abrogated immunoprecipitable
Env but not Gag-Pol production (Fig.
2A,
lanes 5 and 8), while
the frame-preserving SU deletion of CF1

SU
resulted in expression
of the predicted truncated envelope precursor
(Fig.
2A, lane 7).
All of the
env mutants expressed high
levels of RT and other immunoprecipitable
FIV proteins (Fig.
2 and
3),
but none produced any syncytia. In
addition, as shown in Fig.
5, syncytium production in
CF1-transfected
human cells was potently blocked by FIV
Petamula-infected domestic-cat
plasma, with 50% inhibition in 293T and
HeLa cells at 1:32,000-fold
and 1:12,700-fold dilutions, respectively,
while preimmune domestic-cat
plasma had no effect on syncytium
formation at any dilution, even
1:10. In contrast to transfection of
CF1 or CT5, only rare syncytia
containing four to six nuclei were
detectable in HeLa cells 48
to 72 h after transfection of p34TF10.
This result is consistent
with the low level of LTR-directed expression
in HeLa cells (Fig.
2B, lane 2).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 5.
Specific inhibition of CF1-induced syncytium production
in 293T and HeLa cells by FIV-infected domestic-cat plasma. Dilutions
of either FIV-positive (+) (squares and circles) or FIV-negative ( )
(diamonds and triangles) plasma specimens were added to cells at the
time of transfection in 12-well plates (1 µg of DNA/well) and
again with a change of medium 14 h later. Syncytia were scored at
48 h (as foci per well containing at least eight nuclei) by
crystal violet staining of methanol-fixed cells; values are means ± standard deviations of data from three experiments.
|
|
CXCR4 dependence of syncytium induction.
To investigate the
molecular mechanism of fusion mediated by the FIV envelope, human cell
lines which differ in their expression of the principal chemokine
receptors involved in HIV or SIV infection (5, 15) were
studied. Among all human cell lines tested, only U87MG and SK-N-MC
cells failed to produce syncytia after transfection of CF1
(n = 9). Transfection of rodent cells (NIH 3T3, CHO,
and rat 208F) also failed to produce syncytia (n = 8; efficiencies,
10%). However, CF1-transfected rat 208F
cells readily formed syncytia when mixed with a variety of human
cell lines (HeLa, HeLaT4, 293, 293T, Molt4, SupT1, H9, and Jurkat) and
with CrFK cells but did not form syncytia with U87MG or SK-N-MC cells (data not shown). Because CXCR4, the coreceptor for T-cell-line-adapted strains of HIV (16), is expressed in all of the tested human cell lines except U87MG and SK-N-MC, these results suggested
involvement of CXCR4 in FIV envelope glycoprotein-mediated fusion.
To confirm that CXCR4 was specifically responsible for fusion, a
CXCR4-expressing Moloney murine leukemia virus-based retroviral
vector
(pZ.CXCR4) was constructed and used to generate a panel
of
G418-selected cell lines of human, rodent, and feline origin
that
stably express human CXCR4 and neomycin phosphotransferase
from a
bicistronic mRNA. This vector resulted in consistent, sustained
expression of CXCR4 in all G418-selected cell lines, which are
differentiated from control lines by the suffix CXCR4. Figure
6 shows the results of an analysis of
human CXCR4 expression in
these lines and control cell lines, as well
as the relative levels
of feline CXCR4 mRNA expression determined for
feline peripheral
blood mononuclear cells (PBMC) and CrFK cells. Cell
surface expression
of CXCR4, as measured by fluorescence-activated cell
sorter analysis,
correlated closely with mRNA expression (Fig.
6E).

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 6.
Reverse transcription-PCR analysis of human and feline
CXCR4 expression. Cell lines stably expressing human CXCR4 are
designated by the suffix CXCR4 and were generated by G418 selection
after transduction with Moloney murine leukemia virus-based retroviral
vector pZ.CXCR4. RNA was isolated, treated with DNase, and analyzed by
semiquantitative reverse transcription-PCR for human or feline CXCR4
with internal coamplification of a conserved cellular message
(ribosomal protein L32 mRNA). Means of three or more independent
measurements are plotted in panel D, while representative gels are
shown in panels A to C. (A and B) Reverse transcription-PCR of human
CXCR4 (332-bp band) and L32 (120-bp band) for human (open bars in panel
D), rodent (shaded bars in panel D), and feline (closed bars in panel
D) cells. Lane 1, 293T cells; lane 2, HeLa cells; lane 3, HOS cells
(human osteosarcoma); lane 4, HOS.CXCR4 cells; lane 5, U87MG cells;
lane 6, U87MG.CXCR4 cells; lane 7, SK-N-MC cells; lane 8, SK-N-MC.CXCR4
cells; lane 9, 208F rat fibroblasts; lane 10, 208F.CXCR4 cells; lane
11, CrFK cells; lane 12, CrFK.CXCR4 cells; lane 13, 3T3 cells; lane 14, 3T3.CXCR4 cells. , RNA extraction blank; +, repeat HeLa cell positive
control. (C) Feline CXCR4 (497-bp band) and L32 (120-bp band)
expression. Lane 15, CrFK cells; lane 16, fresh Ficoll-purified
F. catus PBMC (FePBMC); lane 17, F. catus PBMC
stimulated for 48 h with phytohemagglutinin P in RPMI with 15%
bovine serum (PHA-P FePBMC). (D) Expression of CXCR4 RNA plotted
relative to L32 mRNA expression for each sample, with subtraction of
local background from each window and correction for relative band
product sizes. Error bars represent standard deviations of three or
more independent measurements. For each sample, PCR was also performed
without reverse transcription to exclude any contribution of DNA to
products, and no bands were detected (data not shown). (E) CXCR4 mRNA
expression, determined above, as described, was plotted against cell
surface expression of human CXCR4, expressed as the ratio of mean
fluorescence intensity of 12G5-PE stained and unstained control cells.
RNA expression was found to be linearly related to CXCR4 expression on
the cell surface (r2 = 0.76, P < 0.02).
|
|
Transfection of CF1 or CT5 into stable U87MG.CXCR4,
SK-N-MC.CXCR4, rat 208F.CXCR4, and murine 3T3.CXCR4 cell
lines derived
with pZ.CXCR4 led to the production of extensive
syncytia, while
simultaneous transfection into the respective
parental lines or
into control lines generated with parental vector
JZ308 yielded
no syncytia (Fig.
4C and D). Moreover, while only rare,
four-
to eight-nucleus syncytia were seen after transfection of CF1
into HOS cells, parallel transfection of CF1 into HOS.CXCR4 cells
resulted in extensive lysis, with multinucleated giant cells containing
more than 100 nuclei (Fig.
4E and F).
These results were specific for CXCR4. In contrast to the
observed strict concordance of cell fusion with CXCR4
expression,
cell lines stably expressing human CCR5 from a similarly
constructed
retroviral vector were not susceptible to FIV 34TF10
envelope
glycoprotein-induced fusion (data not shown).
Single-round infection of human cells by an
env-expressing, pol-deleted FIV
provirus.
To verify the CXCR4 dependence of IV envelope
glycoprotein-induced cell fusion in a single-round viral infection,
34TF10 env was expressed in HeLa, U87MG, and U87MG.CXCR4
cells by using a replication-defective FIV vector. CT5
pol and
CF1
env were cotransfected into 293T cells with the VSV-G expression
plasmid pHCMV-G, generating vector CT5
pol(VSV-G).
Particles generated in this manner contain both FIV envelope
and VSV-G glycoproteins on their surfaces but encode only the FIV
envelope glycoprotein. As shown in infectivity experiments (see below),
the much greater infectivity of VSV-G allows single-round infection of
CXCR4-negative and CXCR4-positive cell lines with equal efficiency.
Each cell line was infected (multiplicity of infection [MOI], 0.2)
with filtered CT5
pol(VSV-G) and examined by FIV-specific
immunoperoxidase staining 34 h later. The FIV LTR was
transcriptionally active in U87MG cells, since CT5
pol(VSV-G)-infected U87MG cells expressed FIV proteins heavily. However, these cells formed no syncytia (Fig. 4G). In contrast, simultaneously infected U87MG.CXCR4 cells displayed equivalent immunostaining but exhibited marked syncytium formation
(Fig. 4H). HeLa cells also exuberantly formed FIV
immunoperoxidase FIA-positive syncytia after CT5
pol(VSV-G)
infection (data not shown).
Infected-cell mixing studies.
Feline cat lymphoma cells
chronically infected with FIV (3201-FIV cells) were mixed with
U87MG, SK-N-MC, HOS, and 3T3 cells, their respective
pZ.CXCR4 vector-selected counterparts, and HeLa cells. Between 12 and
24 h, postinfection, large ballooning syncytia involving 40 to
80% of the monolayer were observed in the HeLa cells and in each
CXCR4-expressing line, while no syncytia were seen at any time point in
control U87MG, SK-N-MC, HOS, or 3T3 cells. The data from these
cell mixing experiments corroborate the results of the
intracellular expression experiments and indicate that CXCR4-specific
fusogenesis is not limited to the FIV 34TF10 clone.
CXCR4-dependent syncytium formation in feline cells.
To
examine whether feline cells were also dependent on CXCR4 for FIV
envelope-mediated syncytium formation, transient
transfection, virus infection, and infection with
replication-defective CT5
pol(VSV-G) were studied. CrFK cells
infected with replication-defective CT5
pol(VSV-G) at a high MOI
(2.0) were strongly positive by immunoperoxidase staining for FIV Env
at 36 h. However, as shown in Fig. 4I, these cells developed
syncytia containing only two to eight nuclei, confirming the
limited fusogenic capacity (2-4, 39, 41) of this cell line.
In marked contrast, CrFK.CXCR4 cells infected with CT5
pol(VSV-G) at
the same MOI showed equal antigen-specific staining but developed
dramatically more syncytia, containing hundreds of nuclei, resulting in
coalescent fusion of the entire monolayer by 36 h (Fig. 4J).
Transient transfection of CF1 into CrFK and CrFK.CXCR4 cells
(n = 6) produced equally discrepant results (data not
shown). Consistent with these results, Fig. 6C shows that CrFK cells
express detectable but low levels of feline CXCR4 mRNA. Note that
CrFK.CXCR4 cells express over 100-fold more human than feline CXCR4
message, relative to L32 RNA (83.6% versus 0.8%), and the expression
of feline CXCR4 is over 10-fold greater in phytohemagglutinin
P-stimulated feline PBMC (9.0%) than in CrFK cells. The abilities
of the cell lines used in this study to support FIV envelope
glycoprotein-induced syncytium production are summarized in Table
1.
Effects of CXCR4 expression on FIV replication kinetics.
The effect of CXCR4 on the replication kinetics of
replication-competent FIV was investigated by infecting CrFK and
CrFK.CXCR4 cells with 34TF10 virus (produced in CrFK cells) and
simultaneously monitoring RT production and syncytium induction. As
shown in Fig. 7, the induction of
syncytia by 34TF10 was dramatically increased in CrFK.CXCR4
cells, resulting in termination on day 7 because of >99% cell death.
Although early-time-point RT values are compressed in the lower part of
the arithmetic ordinate, RT production on days 3 and 5 was also
2.5- and 2.7-fold greater, respectively, in CrFK.CXCR4 cells than
in CrFK cells despite the rapid loss of CrFK.CXCR4 cells.
However, the peak level of RT production was much lower in
CrFK.CXCR4 cells because of this rapid cytolysis (Fig. 7).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 7.
Effect of CXCR4 expression on FIV 34TF10 replication. RT
activity and syncytium formation were simultaneously measured in
cultures of CrFK cells (circles) and CrFK.CXCR4 cells (squares). Open
symbols, RT values; closed symbols, percent syncytium formation.
Results are means ± standard errors of the means of data from
four separate experiments, with RT activity measured in duplicate for
each sample. A total of 2 × 106 cells of each line
were simultaneously plated (day 1) and infected (day 0) with virus
produced in CrFK cells (MOI, 0.01). The difference in cytopathicity was
dramatic, with CrFK.CXCR4 cultures terminated on day 7 because of
>99% cell death.
|
|
Effects of CXCR4 on FIV infectivity.
To determine whether
CXCR4 expression also correlated with an increase in viral
infectivity, the infectivities of wild-type virus and a
replication-defective FIV-enveloped vector on CrFK and CrFK.CXCR4 cells
were measured (Table 2). The
infectivities of replication-competent FIV 34TF10 for CrFK cells was
compared with its infectivity for CrFK.CXCR4 cells by two methods: FIA (34) and, separately, endpoint dilution. By FIA, 34TF10 was 8.2-fold more infectious on CrFK.CXCR4 cells than on CrFK cells (mean ± standard deviation, 9.75 × 104 ± 0.83 × 104 versus 1.19 × 104 ± 0.89 × 104 FFU/ml; P = 0.002, signed Wilcoxon rank sum test). This method might have resulted in the
underestimation of the infectivity ratio, since rounded, floating cells
that stained by the immunoperoxidase method were detected in the
infected CrFK.CXCR4 wells as early as 42 h. Such cells were not
seen in infected or uninfected CrFK cells, suggesting that they
represented rapidly killed, infected cells which were not counted in
the FIA. A comparative endpoint dilution titration of 34TF10 virus on
the two cell lines was therefore performed, and it showed that 34TF10
was 22.6-fold more infective on CrFK.CXCR4 cells than on CrFK
cells (1.15 × 106 versus 5.12 × 104
FFU/ml; P = 0.0001, signed Wilcoxon rank sum test).
The infectivity on CrFK cells of a replication-defective FIV-enveloped
provirus that mimics a single round of viral infection
was also
compared with its infectivity for CrFK.CXCR4 cells by
FIA. Vector,
CT5

pol generated by cotransfection with CF1

env
in 293T
cells, yielded a 12.5-fold-higher titer on CrFK.CXCR4
than on CrFK
cells (6.5 × 10
4 ± 0.9 × 10
4
versus 5.3 × 10
3 ± 0.4 × 10
3
FFU/ml;
P < 0.01, signed Wilcoxon rank sum test).
The mean infectivity
ratio (CrFK.CXCR4/CrFK) for the three sets of
experiments was
14.4. In contrast, no infectivity difference was seen
with VSV-G-pseudotyped
CT5

pol (Fig.
4I and J and Table
2).
FIV infection of human cells.
In agreement with
previous studies, sustained FIV replication was not
observed in human cells. Infection of HeLa or U87MG.CXCR4 cells
(but not U87MG cells) with >105 U of RT from
CT5-transfected 293T cells produced only transient syncytium and RT
production. Similarly, transfection of CT5 or p34TF10 into
human and rodent cell lines failed to result in a sustained, productive FIV infection of cells that did or did not express CXCR4. Virus produced by CT5 transfection of human cells could only generate sustained replication by passage to CrFK or CrFK.CXCR4 cells. Human cell cultures were RT negative by the second split after transfection, and they were immunoperoxidase FIA
negative (except for rare positive cells) by the fourth split. In
contrast, all of these measures produced sustained productive infection of CrFK cells and CrFK.CXCR4 cells (0.5 to 5% of
CrFK.CXCR4 cells survived viral infection and became
chronic producers of greater than 105 U of
RT/ml).
To examine FIV envelope glycoprotein-mediated infection of human cells
quantitatively, while excluding a confounding role
for endogenous
feline retrovirus pseudotypes, filtered supernatant
from 293T
cells cotransfected with CT5

pol and CF1

env was used
to
infect human cells that support FIV LTR-directed
transcription.
Simultaneous infection of U87MG, U87MG.CXCR4, and
HeLa cells with
this FIV-enveloped, replication-defective vector
yielded titers
of <1, 199 ± 16, and 1,096 ± 110 FFU/ml, respectively (
n = 3).
This supernatant
yielded 330- and 60-fold-higher titers on CRFK.CXCR4
cells than on
U87MG.CXCR4 and HeLa cells, respectively. In control
experiments, no
foci were seen in any of these lines exposed to
supernatant from 293T
producer cells transfected with CT5

pol
alone or when a 1:250
dilution of FIV serum was added during infection.
 |
DISCUSSION |
Differences in the tropism, epidemiology, and pathogenetic
features of the primate and nonprimate lentiviruses have made the utility of nonprimate lentivirus infections as models for HIV pathogenesis uncertain. The present systematic study of the molecular prerequisites for FIV expression and infection in both host and nonhost
cells indicates that the life cycles of the primate lentiviruses and
FIV share notable core molecular features.
We conclude that poor promoter activity of the FIV U3 element is
the only block to the productive phase of viral replication in human
cells. Previous reports suggested that more-complex blocks to the
productive phase existed, including poor Rev activity (40). In the present study, replacement of the FIV U3 LTR element with a
heterologous promoter was found to be sufficient for efficient production of infectious virus, demonstrating that the Rev-Rev response
element (RRE) regulatory axis and other productive-phase mechanisms
occur efficiently when the obstacle to efficient transcription is
overcome.
The effects of CXCR4 on infection, fusion, and replication of FIV were
separately examined in the present work. The results, which were
obtained through direct expression of FIV in human and rodent cells for
the first time, corroborate and extend a previous,
methodologically different study that examined mixing CXCR4-expressing
human cell lines with FIV-infected CrFK cells (45). The
data indicate that human CXCR4, but not human CCR5, is sufficient to
specifically mediate infection as well as cell fusion by the FIV 34TF10
SU protein, demonstrating that a common cell surface receptor is
involved in these processes in two distantly related groups of
lentiviruses. Enabling efficient production of infectious FIV in
nonfeline cells also permitted a conclusive study of the molecular
prerequisites for cell fusion and infection free of the possibility of
pseudotyping by xenotropic retroviruses.
We found a comparatively low level of feline CXCR4 expression in CrFK
cells. This finding contrasts with the results of Willett et al.
(45) but is consistent with our finding that FIV Env has a
limited fusogenic capacity in these cells and with the observation by
us and others (2-4, 39, 41) that chronic FIV infection of
CrFK cells is readily established with minimal cell death. Whether this
low-level feline CXCR4 expression and limited cytopathicity result from
heterogeneous CXCR4 expression within the monolayer or from uniformly
low-level expression is uncertain. Also in contrast to the results
obtained by Willett et al. with a different FIV strain (45),
FIV 34TF10 envelope-mediated fusion of most CXCR4-expressing human cell
lines was not inhibited by a monoclonal antibody (MAb) directed against
CXCR4 (MAb 12G5, kindly provided by J. Hoxie through the NIH AIDS
Research Reagent Program). MAb 12G5 did inhibit the fusogenic activity
of CF1 and CT5 in transfected 293 cells, but only at a high
concentration (100 µg/ml for 50% inhibition). This difference in
results may reflect the fact that the activity of 12G5 for inhibition
of HIV-1-induced cell fusion is both viral strain and cell type
dependent (21).
The implications of these data for the reconstruction of lentivirus
evolution are striking: the use of CXCR4, but not of CD4, has either
been conserved since divergence of FIV and primate lentiviruses from a
common ancestor or has evolved independently (convergently). By either
scenario, this common usage is indicative of a fundamental role for
this chemokine receptor in the replication and cytopathicity of
AIDS-causing lentiviruses. Shared utilization of CXCR4 is particularly
intriguing in view of the broad tropism of FIV for B cells,
CD8+ T cells, and CD4+ T cells and its lack of
use of CD4 as a receptor. The uncoupling of selective CD4 depletion
from use of the CD4 molecule for entry is an important distinction
between FIV and HIV infection and suggests that there exist basic
lentivirus pathogenetic mechanisms that are CD4 molecule independent
yet affect this T-cell subset preferentially. Therefore, conservation
of CXCR4 utilization in the two naturally occurring lentivirus
infections that cause immunodeficiency characterized by progressive CD4
depletion suggests that CXCR4 may be central to this and other aspects
of disease causation by both animal and human lentiviruses. In this
regard, emergence of CXCR4-utilizing virus HIV strains in vivo has been
correlated with more-rapid disease progression (19).
The cross-species function of human CXCR4 for infection and syncytium
formation by FIV is also remarkable. This observation is
consistent with recently acquired evidence that C-X-C chemokine receptors can be functionally substituted not only between species but
also between mammalian families. For example, coexpression of murine
(6, 37) or rat (7, 32) CXCR4 (but not CCR5) together with human CD4 has been shown to permit fusion and entry mediated by some HIV-1, but not HIV-2 (33), envelope
glycoproteins. Moreover, F. catus CXCR4 (GenBank accession
no. U92795) is more homologous to human CXCR4 (95% homology at the
amino acid level) than to either rodent molecule (murine, 89%; rat,
91%).
These data demonstrate that few restrictions to the life cycle of this
anciently divergent (11) lentivirus exist in cultured human
cells. Clarification of the precise mechanisms restricting sustained
replication will require a more-detailed study of chimeric viruses and
establishment of whether a primary receptor for FIV exists. Entry may
be mediated by CXCR4 alone, as has been described for HIV-2
(15). Alternatively, a primary receptor molecule could be ubiquitously present on human cells, although the human homolog may
not be used as efficiently for viral entry as the feline homolog. The
effects of repairing ORF2 (43) should also be
examined. The minimal transcriptional activity of the FIV LTR in human
cells in the present study is consistent with previous reports
(17). Restrictions to transcription in human cells may
reside in several motifs, including upstream CTF/NF-1 (
200)
and GATA-1 (
160) sites, an AP-1 site (
116) reported to be
responsible for basal activity in feline cells, and a more
proximal ATF/CRE element (
51) (17, 18, 23-25).
The use of CXCR4 without the constraint of CD4 as a coreceptor
or in combination with a more widely expressed primary receptor may
contribute to the broader lymphocyte tropism of FIV in vivo. Additional
chemokine receptor molecules may be utilized by FIV. The disparity
between the susceptibility of F. catus and other felids to
FIV disease could reflect differences in chemokine receptor interactions. Investigation of ungulate lentiviruses will clarify whether CXCR4 use is a universal lentivirus property.
 |
ACKNOWLEDGMENTS |
We thank M. C. Barr for feline plasma, J. Elder and R. Talbott for p34TF10, J. Zhang and H. Temin for pJZ308, N. Landau and R. Doms for information about CXCR4 expression in human cell lines, T. North for advice about FIV infectivity assays, W. Witke for excellent
technical assistance, F. Mannino for cat blood, and F. Wong-Staal and
the UCSD Center for AIDS Research for shared reagents and equipment.
This work was supported in part by NIH grants 1R01CA6739403, 1U19
AI3661203 (SPIRAT), 3K12DK01408-10S1, and 2P30AI3621404 (CFAR).
 |
FOOTNOTES |
*
Corresponding author. Mailing address for E. M. Poeschla: Department of Medicine 0665, University of California, San
Diego, La Jolla, CA 92093-0665. Phone: (619) 534-4304. Fax: (619)
552-7416. E-mail: epoeschla{at}ucsd.edu. Mailing address for
D. J. Looney: Department of Medicine 0678, University of
California, San Diego, La Jolla, CA 92093-0678. Phone: (619) 552-8585, ext. 2626. Fax: (619) 552-7416. E-mail: dlooney{at}ucsd.edu.
 |
REFERENCES |
| 1.
|
Bachmann, M. H.,
C. Mathiason-Dubard,
G. H. Learn,
A. G. Rodrigo,
D. L. Sodora,
P. Mazzetti,
E. A. Hoover, and J. I. Mullins.
1997.
Genetic diversity of feline immunodeficiency virus: dual infection, recombination, and distinct evolutionary rates among envelope sequence clades.
J. Virol.
71:4241-4253[Abstract].
|
| 2.
|
Bandecchi, P.,
M. Pistello,
D. Matteucci,
S. Lombardi,
M. Bendinelli, and F. Tozzini.
1995.
Examination of variables affecting syncytium formation by, and serum neutralization of, feline immunodeficiency virus on CrFK cells.
New Microbiol.
18:241-252[Medline].
|
| 3.
|
Barr, M. C.,
L. Zou,
D. L. Holzschu,
L. Phillips,
F. W. Scott,
J. W. Casey, and R. J. Avery.
1995.
Isolation of a highly cytopathic lentivirus from a nondomestic cat.
J. Virol.
69:7371-7374[Abstract].
|
| 4.
|
Barr, M. C.,
L. Zou,
F. Long,
W. A. Hoose, and R. J. Avery.
1997.
Proviral organization and sequence analysis of feline immunodeficiency virus isolated from a Pallas' cat.
Virology
228:84-91[Medline].
|
| 5.
|
Berson, J. F.,
D. Long,
B. J. Doranz,
J. Rucker,
F. R. Jirik, and R. W. Doms.
1996.
A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.
J. Virol.
70:6288-6295[Abstract].
|
| 6.
|
Bieniasz, P. D.,
R. A. Fridell,
K. Anthony, and B. R. Cullen.
1997.
Murine CXCR-4 is a functional coreceptor for T-cell-tropic and dual-tropic strains of human immunodeficiency virus type 1.
J. Virol.
71:7097-7100[Abstract].
|
| 7.
|
Brelot, A.,
N. Heveker,
O. Pleskoff,
N. Sol, and M. Alizon.
1997.
Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity.
J. Virol.
71:4744-4751[Abstract].
|
| 8.
|
Brown, E. W.,
N. Yuhki,
C. Packer, and S. J. O'Brien.
1994.
A lion lentivirus related to feline immunodeficiency virus: epidemiologic and phylogenetic aspects.
J. Virol.
68:5953-5968[Abstract/Free Full Text].
|
| 9.
|
Brown, W. C.,
L. Bissey,
K. S. Logan,
N. C. Pedersen,
J. H. Elder, and E. W. Collisson.
1991.
Feline immunodeficiency virus infects both CD4+ and CD8+ T lymphocytes.
J. Virol.
65:3359-3364[Abstract/Free Full Text].
|
| 10.
|
Burns, J. C.,
T. Friedmann,
W. Driever,
M. Burrascano, and J. K. Yee.
1993.
Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells.
Proc. Natl. Acad. Sci. USA
90:8033-8037[Abstract/Free Full Text].
|
| 11.
|
Carpenter, M. A., and S. J. O'Brien.
1995.
Coadaptation and immunodeficiency virus: lessons from the Felidae.
Curr. Opin. Genet. Dev.
5:739-745[Medline].
|
| 12.
|
Clements, J. E., and M. C. Zink.
1996.
Molecular biology and pathogenesis of animal lentivirus infections.
Clin. Microbiol. Rev.
9:100-117[Abstract].
|
| 13.
|
de Parseval, A.,
D. L. Lerner,
P. Borrow,
B. J. Willett, and J. H. Elder.
1997.
Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding.
J. Virol.
71:5742-5749[Abstract].
|
| 14.
|
Elder, J. H., and T. R. Phillips.
1993.
Molecular properties of feline immunodeficiency virus (FIV).
Infect. Agents Dis.
2:361-374[Medline].
|
| 15.
|
Endres, M. J.,
P. R. Clapham,
M. Marsh,
M. Ahuja,
J. D. Turner,
A. McKnight,
J. F. Thomas,
B. Stoebenau-Haggarty,
S. Choe,
P. J. Vance,
T. N. Wells,
C. A. Power,
S. S. Sutterwala,
R. W. Doms,
N. R. Landau, and J. A. Hoxie.
1996.
CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.
Cell
87:745-756[Medline].
|
| 16.
|
Feng, Y.,
C. C. Broder,
P. E. Kennedy, and E. A. Berger.
1996.
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science
272:872-877[Abstract].
|
| 17.
|
Ikeda, Y.,
K. Tomonaga,
Y. Kawaguchi,
M. Kohmoto,
Y. Inoshimu,
Y. Tohya,
T. Miyazawa,
C. Kai, and T. Mikami.
1996.
Feline immunodeficiency virus can infect a human cell line (MOLT-4) but establishes a state of latency in the cells.
J. Gen. Virol.
77:1623-1630[Abstract/Free Full Text].
|
| 18.
|
Inoshima, Y.,
M. Kohmoto,
Y. Ikeda,
H. Yamada,
Y. Kawaguchi,
K. Tomonaga,
T. Miyazawa,
C. Kai,
T. Umemura, and T. Mikami.
1996.
Roles of the auxiliary genes and AP-1 binding site in the long terminal repeat of feline immunodeficiency virus in the early stage of infection in cats.
J. Virol.
70:8518-8526[Abstract].
|
| 19.
|
Lu, Z.,
J. F. Berson,
Y. Chen,
J. D. Turner,
T. Zhang,
M. Sharron,
M. H. Jenks,
Z. Wang,
J. Kim,
J. Rucker,
J. A. Hoxie,
S. C. Peiper, and R. W. Doms.
1997.
Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains.
Proc. Natl. Acad. Sci. USA
94:6426-6431[Abstract/Free Full Text].
|
| 20.
|
McAllister, R. M.,
M. Nicolson,
M. B. Gardner,
R. W. Rongey,
S. Rasheed,
P. S. Sarma,
R. J. Huebner,
M. Hatanaka,
S. Oroszlan,
R. V. Gilden,
A. Kabigting, and L. Vernon.
1972.
C-type virus released from cultured human rhabdomyosarcoma cells.
Nat. New Biol.
235:3-6[Medline].
|
| 21.
|
McKnight, A.,
D. Wilkinson,
G. Simmons,
S. Talbot,
L. Picard,
M. Ahuja,
M. Marsh,
J. A. Hoxie, and P. R. Clapham.
1997.
Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent.
J. Virol.
71:1692-1696[Abstract].
|
| 22.
|
Miyazawa, T.,
Y. Kawaguchi,
M. Kohmoto,
J. Sakuragi,
A. Adachi,
M. Fukasawa, and T. Mikami.
1992.
Production of feline immunodeficiency virus in feline and non-feline non-lymphoid cell lines by transfection of an infectious molecular clone.
J. Gen. Virol.
73:1543-1546[Abstract/Free Full Text].
|
| 23.
|
Miyazawa, T.,
M. Kohmoto,
Y. Kawaguchi,
K. Tomonaga,
T. Toyosaki,
K. Ikuta,
A. Adachi, and T. Mikami.
1993.
The AP-1 binding site in the feline T lymphocytes.
J. Gen. Virol.
74:1573-1580[Abstract/Free Full Text].
|
| 24.
|
Miyazawa, T.,
K. Tomonaga,
Y. Kawaguchi,
M. Kohmoto,
Y. Inoshima,
K. Maeda,
T. Mikami, and K. Maedadel.
1994.
Effects of insertion of multiple AP-1 binding sites into the U3 region of the long terminal repeat of feline immunodeficiency virus.
Arch. Virol.
139:37-48[Medline]. (Erratum, 140:621, 1995.)
|
| 25.
|
Miyazawa, T.,
K. Tomonaga,
Y. Kawaguchi, and T. Mikami.
1994.
The genome of feline immunodeficiency virus.
Arch. Virol.
134:221-234[Medline].
|
| 26.
|
Novotney, C.,
R. V. English,
J. Housman,
M. G. Davidson,
M. P. Nasisse,
C. R. Jeng,
W. C. Davis, and M. B. Tompkins.
1990.
Lymphocyte population changes in cats naturally infected with feline immunodeficiency virus.
AIDS
4:1213-1218[Medline].
|
| 27.
|
Olmsted, R. A.,
A. K. Barnes,
J. K. Yamamoto,
V. M. Hirsch,
R. H. Purcell, and P. R. Johnson.
1989.
Molecular cloning of feline immunodeficiency virus.
Proc. Natl. Acad. Sci. USA
86:2448-2452[Abstract/Free Full Text].
|
| 28.
|
Olmsted, R. A.,
V. M. Hirsch,
R. H. Purcell, and P. R. Johnson.
1989.
Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses.
Proc. Natl. Acad. Sci. USA
86:8088-8092[Abstract/Free Full Text].
|
| 29.
|
Olmsted, R. A.,
R. Langley,
M. E. Roelke,
R. M. Goeken,
D. Adger-Johnson,
J. P. Goff,
J. P. Albert,
C. Packer,
M. K. Laurenson,
T. M. Caro,
L. Scheepers,
D. E. Wildt,
M. Bush,
J. S. Martenson, and S. J. O'Brien.
1992.
Worldwide prevalence of lentivirus infection in wild feline species: epidemiologic and phylogenetic aspects.
J. Virol.
66:6008-6018[Abstract/Free Full Text].
|
| 30.
|
Pedersen, N. C.
1993.
The feline immunodeficiency virus, p. 181-228.
In
J. A. Levy (ed.), The Retroviridae. Plenum Press, New York, N.Y.
|
| 31.
|
Pedersen, N. C.,
E. W. Ho,
M. L. Brown, and J. K. Yamamoto.
1987.
Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.
Science
235:790-793[Abstract/Free Full Text].
|
| 32.
|
Pleskoff, O.,
N. Sol,
B. Labrosse, and M. Alizon.
1997.
Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR-4 (fusin).
J. Virol.
71:3259-3262[Abstract].
|
| 33.
|
Potempa, S.,
L. Picard,
J. D. Reeves,
D. Wilkinson,
R. A. Weiss, and S. J. Talbot.
1997.
CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: the role of the N-terminal domain of CXCR-4 in fusion and entry.
J. Virol.
71:4419-4424[Abstract].
|
| 34.
|
Remington, K. M.,
B. Chesebro,
K. Wehrly,
N. C. Pedersen, and T. W. North.
1991.
Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.
J. Virol.
65:308-312[Abstract/Free Full Text].
|
| 35.
|
Sparger, E. E.,
B. L. Shacklett,
L. Renshaw-Gegg,
P. A. Barry,
N. C. Pedersen,
J. H. Elder, and P. A. Luciw.
1992.
Regulation of gene expression directed by the long terminal repeat of the feline immunodeficiency virus.
Virology
187:165-177[Medline].
|
| 36.
|
Spearman, C.
1908.
The method of right and wrong cases (constant stimuli) without Gauss's formulae.
Br. J. Psychol.
2:227-242.
|
| 37.
|
Tachibana, K.,
T. Nakajima,
A. Sato,
K. Igarashi,
H. Shida,
H. Iizasa,
N. Yoshida,
O. Yoshie,
T. Kishimoto, and T. Nagasawa.
1997.
CXCR4/fusin is not a species-specific barrier in murine cells for HIV-1 entry.
J. Exp. Med.
185:1865-1870[Abstract/Free Full Text].
|
| 38.
|
Takeuchi, Y.,
F.-L. Cosset,
P. J. Lachmann,
H. Okada,
R. A. Weiss, and M. K. L. Collins.
1994.
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell.
J. Virol.
68:8001-8007[Abstract/Free Full Text].
|
| 39.
|
Talbott, R. L.,
E. E. Sparger,
K. M. Lovelace,
W. M. Fitch,
N. C. Pedersen,
P. A. Luciw, and J. H. Elder.
1989.
Nucleotide sequence and genomic organization of feline immunodeficiency virus.
Proc. Natl. Acad. Sci. USA
86:5743-5747[Abstract/Free Full Text].
|
| 40.
|
Tomonaga, K.,
T. Miyazawa,
Y. Kawaguchi,
M. Kohmoto,
Y. Inoshima, and T. Mikami.
1994.
Comparison of the Rev transactivation of feline immunodeficiency virus in feline and non-feline cell lines.
J. Vet. Med. Sci.
56:199-201[Medline].
|
| 41.
|
Tozzini, F.,
D. Matteucci,
P. Bandecchi,
F. Baldinotti,
A. Poli,
M. Pistello,
K. H. Siebelink,
L. Ceccherini-Nelli, and M. Bendinelli.
1992.
Simple in vitro methods for titrating feline immunodeficiency virus (FIV) and FIV neutralizing antibodies.
J. Virol. Methods
37:241-252[Medline].
|
| 42.
|
Wagaman, P. C.,
C. S. Hasselkus-Light,
M. Henson,
D. L. Lerner,
T. R. Phillips, and J. H. Elder.
1993.
Molecular cloning and characterization of deoxyuridine triphosphatase from feline immunodeficiency virus (FIV).
Virology
196:451-457[Medline].
|
| 43.
|
Waters, A. K.,
A. P. De Parseval,
D. L. Lerner,
J. C. Neil,
F. J. Thompson, and J. H. Elder.
1996.
Influence of ORF2 on host cell tropism of feline immunodeficiency virus.
Virology
215:10-16[Medline].
|
| 44.
|
Willett, B. J.,
M. J. Hosie,
O. Jarrett, and J. C. Neil.
1994.
Identification of a putative cellular receptor for feline immunodeficiency virus as the feline homologue of CD9.
Immunology
81:228-233[Medline].
|
| 45.
|
Willett, B. J.,
L. Picard,
M. J. Hosie,
J. D. Turner,
K. Adema, and P. R. Clapham.
1997.
Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses.
J. Virol.
71:6407-6415[Abstract].
|
| 46.
|
Willey, R. L.,
D. H. Smith,
L. A. Lasky,
T. S. Theodore,
P. L. Earl,
B. Moss,
D. J. Capon, and M. A. Martin.
1988.
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.
J. Virol.
62:139-147[Abstract/Free Full Text].
|
| 47.
|
Zhang, J., and H. M. Temin.
1993.
Rate and mechanism of nonhomologous recombination during a single cycle of retroviral replication.
Science
259:234-238[Abstract/Free Full Text].
|
J Virol, August 1998, p. 6858-6866, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Saenz, D. T., Teo, W., Olsen, J. C., Poeschla, E. M.
(2005). Restriction of Feline Immunodeficiency Virus by Ref1, Lv1, and Primate TRIM5{alpha} Proteins. J. Virol.
79: 15175-15188
[Abstract]
[Full Text]
-
de Rozieres, S., Mathiason, C. K., Rolston, M. R., Chatterji, U., Hoover, E. A., Elder, J. H.
(2004). Characterization of a Highly Pathogenic Molecular Clone of Feline Immunodeficiency Virus Clade C. J. Virol.
78: 8971-8982
[Abstract]
[Full Text]
-
de Parseval, A., Ngo, S., Sun, P., Elder, J. H.
(2004). Factors That Increase the Effective Concentration of CXCR4 Dictate Feline Immunodeficiency Virus Tropism and Kinetics of Replication. J. Virol.
78: 9132-9143
[Abstract]
[Full Text]
-
Saenz, D. T., Loewen, N., Peretz, M., Whitwam, T., Barraza, R., Howell, K. G., Holmes, J. M., Good, M., Poeschla, E. M.
(2004). Unintegrated Lentivirus DNA Persistence and Accessibility to Expression in Nondividing Cells: Analysis with Class I Integrase Mutants. J. Virol.
78: 2906-2920
[Abstract]
[Full Text]
-
Kohmoto, M., Ikeda, Y., Sato, E., Nishimura, Y., Inoshima, Y., Shimojima, M., Tohya, Y., Mikami, T., Miyazawa, T.
(2003). Experimental Mucosal Infection with Molecularly Cloned Feline Immunodeficiency Viruses. CVI
10: 185-188
[Abstract]
[Full Text]
-
Loewen, N., Bahler, C., Teo, W.-l., Whitwam, T., Peretz, M., Xu, R., Fautsch, M. P., Johnson, D. H., Poeschla, E. M.
(2002). Preservation of Aqueous Outflow Facility after Second-Generation FIV Vector-Mediated Expression of Marker Genes in Anterior Segments of Human Eyes. IOVS
43: 3686-3690
[Abstract]
[Full Text]
-
Kemler, I., Barraza, R., Poeschla, E. M.
(2002). Mapping the Encapsidation Determinants of Feline Immunodeficiency Virus. J. Virol.
76: 11889-11903
[Abstract]
[Full Text]
-
Willett, B. J., Cannon, C. A., Hosie, M. J.
(2002). Upregulation of Surface Feline CXCR4 Expression following Ectopic Expression of CCR5: Implications for Studies of the Cell Tropism of Feline Immunodeficiency Virus. J. Virol.
76: 9242-9252
[Abstract]
[Full Text]
-
Patrick, M. K., Johnston, J. B., Power, C.
(2002). Lentiviral Neuropathogenesis: Comparative Neuroinvasion, Neurotropism, Neurovirulence, and Host Neurosusceptibility. J. Virol.
76: 7923-7931
[Full Text]
-
Obert, L. A., Hoover, E. A.
(2002). Early Pathogenesis of Transmucosal Feline Immunodeficiency Virus Infection. J. Virol.
76: 6311-6322
[Abstract]
[Full Text]
-
Johnston, J. B., Power, C.
(2002). Feline Immunodeficiency Virus Xenoinfection: the Role of Chemokine Receptors and Envelope Diversity. J. Virol.
76: 3626-3636
[Abstract]
[Full Text]
-
Whitwam, T., Peretz, M., Poeschla, E.
(2001). Identification of a Central DNA Flap in Feline Immunodeficiency Virus. J. Virol.
75: 9407-9414
[Abstract]
[Full Text]
-
Frey, S. C. S., Hoover, E. A., Mullins, J. I.
(2001). Feline Immunodeficiency Virus Cell Entry. J. Virol.
75: 5433-5440
[Abstract]
[Full Text]
-
de Parseval, A., Elder, J. H.
(2001). Binding of Recombinant Feline Immunodeficiency Virus Surface Glycoprotein to Feline Cells: Role of CXCR4, Cell-Surface Heparans, and an Unidentified Non-CXCR4 Receptor. J. Virol.
75: 4528-4539
[Abstract]
[Full Text]
-
Mori, T., Boyd, M. R.
(2001). Cyanovirin-N, a Potent Human Immunodeficiency Virus-Inactivating Protein, Blocks both CD4-Dependent and CD4-Independent Binding of Soluble gp120 (sgp120) to Target Cells, Inhibits sCD4-Induced Binding of sgp120 to Cell-Associated CXCR4, and Dissociates Bound sgp120 from Target Cells. Antimicrob. Agents Chemother.
45: 664-672
[Abstract]
[Full Text]
-
Bigornia, L., Lockridge, K. M., Sparger, E. E.
(2001). Construction and In Vitro Characterization of Attenuated Feline Immunodeficiency Virus Long Terminal Repeat Mutant Viruses. J. Virol.
75: 1054-1060
[Abstract]
[Full Text]
-
Dey, B., Lerner, D. L., Lusso, P., Boyd, M. R., Elder, J. H., Berger, E. A.
(2000). Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses. J. Virol.
74: 4562-4569
[Abstract]
[Full Text]
-
Lerner, D. L., Elder, J. H.
(2000). Expanded Host Cell Tropism and Cytopathic Properties of Feline Immunodeficiency Virus Strain PPR Subsequent to Passage through Interleukin-2-Independent T Cells. J. Virol.
74: 1854-1863
[Abstract]
[Full Text]
-
Vahlenkamp, T. W., De Ronde, A., Schuurman, N. N. M. P., van Vliet, A. L. W., van Drunen, J., Horzinek, M. C., Egberink, H. F.
(1999). Envelope gene sequences encoding variable regions 3 and 4 are involved in macrophage tropism of feline immunodeficiency virus. J. Gen. Virol.
80: 2639-2646
[Abstract]
[Full Text]
-
Dow, S. W., Mathiason, C. K., Hoover, E. A.
(1999). In Vivo Monocyte Tropism of Pathogenic Feline Immunodeficiency Viruses. J. Virol.
73: 6852-6861
[Abstract]
[Full Text]
-
Richardson, J., Pancino, G., Merat, R., Leste-Lasserre, T., Moraillon, A., Schneider-Mergener, J., Alizon, M., Sonigo, P., Heveker, N.
(1999). Shared Usage of the Chemokine Receptor CXCR4 by Primary and Laboratory-Adapted Strains of Feline Immunodeficiency Virus. J. Virol.
73: 3661-3671
[Abstract]
[Full Text]
-
Edinger, A. L., Blanpain, C., Kunstman, K. J., Wolinsky, S. M., Parmentier, M., Doms, R. W.
(1999). Functional Dissection of CCR5 Coreceptor Function through the Use of CD4-Independent Simian Immunodeficiency Virus Strains. J. Virol.
73: 4062-4073
[Abstract]
[Full Text]
-
Brelot, A., Heveker, N., Adema, K., Hosie, M. J., Willett, B., Alizon, M.
(1999). Effect of Mutations in the Second Extracellular Loop of CXCR4 on Its Utilization by Human and Feline Immunodeficiency Viruses. J. Virol.
73: 2576-2586
[Abstract]
[Full Text]
-
Johnston, J., Power, C.
(1999). Productive Infection of Human Peripheral Blood Mononuclear Cells by Feline Immunodeficiency Virus: Implications for Vector Development. J. Virol.
73: 2491-2498
[Abstract]
[Full Text]